Alnylam hits ‘home run’ in clinical trial, shares rise 35%

Investors and onlookers expect the data to be a big financial boost for the company. Alnylam’s (Nasdaq: ALNY) shares hit a new 52-week high on Monday after the Phase 3 readout.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks